UNASSIGNED: While selective @entity817 inhibitors have demonstrated improved outcomes in @entity1 with metastatic @entity817 @entity8554 mutant @entity320 , management of brain @entity3 prior to and during therapy presents challenges. Stereotactic radiosurgery (SRS) is an effective treatment for @entity320 brain @entity3 , but there is limited safety and efficacy data on the use of SRS during @entity817 therapy. An analysis was performed of @entity1 with @entity320 and brain @entity3 treated with SRS while on @entity5457 . MRI scans were reviewed post-SRS to evaluate local control (LC) as well as distant control. We identified 80 metastatic @entity75 treated in 24 @entity1 . The median planning target volume was 0.28  cm(3) (range 0.05-4.19  cm(3)), and lesions were treated to a median dose of 24  Gy (range 15-24  Gy). The median follow up was 5.1  months (range 2-25.2  months). Eight (10  %) lesions showed progression at a median of 6.1  months (range 2-20.1  months) following SRS. Kaplan-Meier LC estimates at 6 and 12  months were 92 and 75  %, respectively. Fourteen (58  %) @entity1 were noted to have distant brain failure at a median of 3.4  months (range 1.9-16.1  months) following treatment with SRS. Median overall (OS) from the date of SRS was 7.2  months (range 1.5-26.8  months) with a median of 11.9  months (range 1.5-28.5  months) since the date of brain @entity3 diagnosis. There was no evidence of increased @entity137 with the combination of SRS and @entity5457 . SRS to brain @entity3 appears to be both safe and effective for @entity1 treated concurrently with @entity817 inhibitors.

LINAC-based stereotactic radiosurgery to the brain with concurrent @entity5457 for @entity320 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity75 :: ('MESH:D001927', 'Disease') :: ['melanoma brain lesions'] @entity8554 :: ('p|SUB|V|600|E', 'ProteinMutation') :: ['V600E'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma'] @entity5457 :: ('MESH:C551177', 'Chemical') :: ['vemurafenib']
@entity3 :: (MESH:D009362,Disease) :: ['metastases']
